FDA Approves Combination Of Ezetimibe And Atorvastatin

The FDA has approved a new combination drug from Merck for lowering cholesterol. The drug, which will carry the brand name of Liptruzet, is a combination of two previously approved cholesterol-lowering drugs, ezetimibe and atorvastatin. Merck said the new drug (pronounced “LIP-true-zett”) would be commercially available starting next week. Liptruzet will be available as a once-daily tablet combining 10 mg of ezetimibe with either 10, 20, 40, or 80 mg of atorvastatin. In clinical trials Liptruzet lowered LDL cholesterol from 53% to 61%, depending on dosage. … Click here to read the full post on More…
Source: CardioBrief - Category: Cardiology Authors: Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes atorvastatin ezetimibe FDA food and drug administration Low-density lipoprotein Merck Merck & Co statins vytorin Source Type: blogs